Docket Number:
FDA-2017-N-5925
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This guidance provides recommendations on fulfilling the new labeling requirements for susceptibility test interpretive criteria for prescription systemic antibacterial and antifungal
drugs as established by section 3044 of the 21st Century Cures Act (Cures Act) (Public Law 114-255).

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2017-N-5925.